In ER+ breast cancers, CD146 distinguishes two CAF subgroups: CD146+ CAFs maintain ER expression, estrogen-dependent proliferation, and sensitivity to tamoxifen, whereas CD146− CAFs play the opposite role [207]. This evidence concerns the gene MCAM and breast carcinoma.